Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has... see more

Recent & Breaking News (NDAQ:CRSP)

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

GlobeNewswire 8 days ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2026

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112(TM)) in Autoimmune Diseases and Hematologic Malignancies

GlobeNewswire December 22, 2025

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Canada NewsWire December 9, 2025

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

GlobeNewswire November 10, 2025

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

GlobeNewswire November 8, 2025

CRISPR Therapeutics Presents New Preclinical Data for CTX460(TM) Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase(TM) Editing Platform

GlobeNewswire October 10, 2025

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

GlobeNewswire October 1, 2025

CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

GlobeNewswire September 22, 2025

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

GlobeNewswire September 9, 2025

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 2, 2025

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

GlobeNewswire August 4, 2025

CRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025

GlobeNewswire June 30, 2025

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310(TM) Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

GlobeNewswire June 26, 2025

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 29, 2025

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

GlobeNewswire May 19, 2025

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310(TM) Targeting ANGPTL3

GlobeNewswire May 6, 2025

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2025

CRISPR Therapeutics Announces Transition of Chief Operating Officer

GlobeNewswire March 26, 2025

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 26, 2025

Podcasts